# Freenome Holdings

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/freenome-holdings

- Industry: Biotechnology
- Headquarters: Brisbane, US
- Website: www.freenome.com
- Total disclosed funding: $1.3B
- Latest round: Series F (Feb 15, 2024)
- Investors on record: 47

## About

Freenome Holdings, Inc. is a pioneering biotechnology company in the U.S. that focuses on early cancer detection using advanced multiomics technology and artificial intelligence through blood-based screening solutions.Freenome Holdings, Inc. specializes in developing innovative cancer screening platforms that leverage artificial intelligence and multiomics technology. Founded in 2014 in Brisbane, US, the company has undergone various funding rounds and partnerships to enhance its offerings. Charles Roberts, the founder, has a history of previous entrepreneurial ventures. Their most recent funding round, the Series F, raised USD 254.00 mn on February 15, 2024, with participation from Roche Venture Fund and others, bringing their total amount raised to USD 254.00 mn and current valuation to USD 1,962.73 mn.Freenome specializes in early cancer detection through its innovative screening platform that integrates advanced science with artificial intelligence. The core product offerings revolve around multiomics technology, which utilizes a standard blood draw to identify cancer in its earliest and most treatable stages. This intelligent screening platform aims to address critical healthcare challenges by enabling timely interventions for cancer patients, thereby improving treatment outcomes. Freenome's services are designed for healthcare providers, oncologists, and clinical laboratories, ensuring that end users—patients and their families—receive accurate and accessible cancer screening solutions. The company operates primarily in the United States, with plans to expand its reach into other international markets as it progresses through clinical validations and regulatory approvals.Freenome generates revenue through partnerships with healthcare institutions and clinical labs that integrate its screening solutions into their services. The transactions are structured primarily as B2B agreements, allowing healthcare providers to offer Freenome’s cancer detection tests to their patients. The company promotes its flagship offerings, including the FREENOME® test and the PREEMPT CRC® study, through subscription models and service agreements tailored to the needs of its clients. These partnerships enhance the clinical workflow while providing Freenome a steady revenue stream as healthcare providers incorporate its products into their routine cancer screening protocols. The pricing structure reflects the value of early detection and the potential cost savings associated with timely medical interventions.The company aims to utilize the recently raised USD 254.00 mn in Series F funding to advance its clinical programs and expand its platform capabilities. Freenome plans to launch new products designed for enhanced cancer detection and is targeting expansion into international markets as it achieves clinical validations and regulatory approvals. With this funding, the organization is positioned to accelerate its efforts in improving cancer screening technologies and increasing accessibility to its services.

## Funding rounds

- Series F, Feb 15, 2024, $254M — Bain Capital, Polaris Partners, ARTIS Ventures, Andreessen Horowitz, ArrowMark Partners, Roche Venture Fund, DCVC, Pura Vida Investments, RA Capital Management, Cormorant Asset Management, Squarepoint, Perceptive Advisors, Eventide Asset Management, Sands Capital Alternatives, Section 32, Quest Diagnostics, Intermountain Ventures, BrightEdge Ventures, Ark Invest
- Series E, Jan 11, 2022, $290M — Roche Venture Fund
- Series D, Nov 22, 2021, $243M — Bain Capital, T Rowe Price, Polaris Partners, HBM Partners, Novartis Venture Fund, Fidelity Investments, ARTIS Ventures, GV, Andreessen Horowitz, ArrowMark Partners, Roche Venture Fund, Kaiser Permanente Ventures, Suvretta Capital Management, DCVC, Pura Vida Investments, RA Capital Management, Rock Springs Capital, Cormorant Asset Management, Farallon Capital Management, Janus Henderson Investors, Perceptive Advisors, Eventide Asset Management, Sands Capital Alternatives, Section 32, Ridgeback Asset Management, Soleus Capital, Intermountain Ventures, Logos Capital, BrightEdge Ventures, Catalio Capital Management, Byers Capital
- Series C, Aug 14, 2020, $270M — Bain Capital, T Rowe Price, Polaris Partners, Novartis Venture Fund, Fidelity Investments, GV, Andreessen Horowitz, Roche Venture Fund, Kaiser Permanente Ventures, DCVC, RA Capital Management, EcoR1 Capital, Rock Springs Capital, Cormorant Asset Management, Farallon Capital Management, Janus Henderson Investors, Perceptive Advisors, Sands Capital Alternatives, Section 32, Soleus Capital, BrightEdge Ventures, Catalio Capital Management, Colorectal Cancer Alliance
- Series B, Jun 24, 2019, $160M — T Rowe Price, Polaris Partners, GV, Andreessen Horowitz, Roche Venture Fund, Kaiser Permanente Ventures, DCVC, RA Capital Management, Perceptive Advisors, Section 32, Verily Life Sciences LLC, Agent Capital, CEC Capital, BrightEdge Ventures
- Series A, Aug 14, 2017, $8.1M — Section 32, Verily Life Sciences LLC
- Series A, Feb 23, 2017, $64M — CRV, Polaris Partners, Allen & Company, Founders Fund, Asset Management Ventures, GV, Andreessen Horowitz, Innovation Endeavors, DCVC, AME Cloud Ventures, S28 Capital
- Seed, May 23, 2016, $5.5M — Founders Fund, Andreessen Horowitz, DCVC, Third Kind Venture Capital

## Investors

- Founders Fund (https://capitalatlas.ai/funds/founders-fund) — Seed, Series A
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Seed, Series A, Series B, Series C, Series D, Series F
- DCVC (https://capitalatlas.ai/funds/dcvc) — Seed, Series A, Series B, Series C, Series D, Series F
- Third Kind Venture Capital (https://capitalatlas.ai/funds/third-kind-venture-capital) — Seed
- CRV (https://capitalatlas.ai/funds/crv) — Series A
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C, Series D, Series F
- Allen & Company — Series A
- Asset Management Ventures (https://capitalatlas.ai/funds/asset-management-ventures) — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B, Series C, Series D
- Innovation Endeavors (https://capitalatlas.ai/funds/innovation-endeavors) — Series A
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Series A
- S28 Capital (https://capitalatlas.ai/funds/s28-capital) — Series A
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series A, Series B, Series C, Series D, Series F
- Verily Life Sciences LLC — Series A, Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B, Series C, Series D
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series B, Series C, Series D, Series E, Series F
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series B, Series C, Series D
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C, Series D, Series F
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B, Series C, Series D, Series F
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series B
- CEC Capital (https://capitalatlas.ai/funds/cec-capital) — Series B
- BrightEdge Ventures (https://capitalatlas.ai/funds/brightedge-ventures) — Series B, Series C, Series D, Series F
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series C, Series D, Series F
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series C, Series D
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C, Series D
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series C
- Rock Springs Capital — Series C, Series D
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C, Series D, Series F
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series C, Series D
- Janus Henderson Investors — Series C, Series D
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series C, Series D, Series F
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series C, Series D
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series C, Series D
- Colorectal Cancer Alliance — Series C
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series D
- ARTIS Ventures (https://capitalatlas.ai/funds/artis-ventures) — Series D, Series F
- ArrowMark Partners — Series D, Series F
- Suvretta Capital Management — Series D
- Pura Vida Investments (https://capitalatlas.ai/funds/pura-vida-investments) — Series D, Series F
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series D, Series F
- Ridgeback Asset Management — Series D
- Intermountain Ventures (https://capitalatlas.ai/funds/intermountain-ventures) — Series D, Series F
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series D
- Byers Capital (https://capitalatlas.ai/funds/byers-capital) — Series D
- Squarepoint — Series F
- Quest Diagnostics — Series F
- Ark Invest (https://capitalatlas.ai/funds/ark-invest) — Series F